Sherry Adkins
Overview
Explore the profile of Sherry Adkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Small P, Adkins S, Bell A
MedEdPORTAL
. 2024 Dec;
20:11478.
PMID: 39737337
Introduction: Physicians face barriers to counseling patients regarding lifestyle, specifically, low perceived importance of and confidence in counseling, leading to underuse. There is a dearth in the literature evaluating educational...
2.
Adkins S, Reynolds P, Rabah K, Flowers S
MedEdPORTAL
. 2024 Oct;
20:11451.
PMID: 39391216
Introduction: Medical error is common and has a significant impact on physicians, learners, and patients' perception of the medical system; however, residents receive little formal training on this topic. This...
3.
Adkins S, Altaany R, Brar K, Kauser H, Hughbanks S, Rabah K, et al.
J Med Educ Curric Dev
. 2024 Aug;
11:23821205241272358.
PMID: 39149530
Objectives: Medical error is common and significantly impacts patients, physicians, learners, and public perception of the medical system; however, residents receive little formal training on this topic. Research on error...
4.
Jallouk A, Kui N, Sun R, Westin J, Steiner R, Nair R, et al.
Haematologica
. 2023 Nov;
109(5):1460-1468.
PMID: 38031807
Complications occurring after lymphodepleting chemotherapy (LDC) may delay chimeric antigen receptor (CAR) T-cell infusion. The effect of these delays on clinical outcomes is unclear. We performed a retrospective analysis of...
5.
Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, et al.
Blood Adv
. 2023 Jun;
7(21):6785-6789.
PMID: 37389847
No abstract available.
6.
Schneider B, Naidoo J, Santomasso B, Lacchetti C, Adkins S, Anadkat M, et al.
J Clin Oncol
. 2021 Nov;
39(36):4073-4126.
PMID: 34724392
Purpose: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods: A multidisciplinary...
7.
Santomasso B, Nastoupil L, Adkins S, Lacchetti C, Schneider B, Anadkat M, et al.
J Clin Oncol
. 2021 Nov;
39(35):3978-3992.
PMID: 34724386
Purpose: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with chimeric antigen receptor (CAR) T-cell therapy. Methods: A...
8.
Strati P, Ahmed S, Furqan F, Fayad L, Lee H, Iyer S, et al.
Blood
. 2021 Feb;
137(23):3272-3276.
PMID: 33534891
Corticosteroids are commonly used for the management of severe toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether their dose, duration, and timing may affect...
9.
Adkins S
J Adv Pract Oncol
. 2021 Feb;
10(Suppl 3):21-28.
PMID: 33520343
Chimeric antigen receptor (CAR) T-cell therapy is an exciting innovation in the treatment of cancer. However, CAR T-cell therapies have been associated with unique adverse events (AEs), including cytokine release...
10.
Adkins S
J Adv Pract Oncol
. 2021 Jan;
10(8):833-843.
PMID: 33425467
CAR T-cell therapy is rapidly emerging as a promising treatment for many hematologic malignancies. However, CAR T cells can be associated with unique toxicities, including cytokine release syndrome (CRS), which...